RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ProQR Therapeutics Stock

ProQR Therapeutics ROCE 2024

ProQR Therapeutics ROCE

-0.77

Ticker

PRQR

ISIN

NL0010872495

WKN

A12B97

In 2024, ProQR Therapeutics's return on capital employed (ROCE) was -0.77, a -22.1% increase from the -0.99 ROCE in the previous year.

ProQR Therapeutics Aktienanalyse

What does ProQR Therapeutics do?

ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling ProQR Therapeutics's Return on Capital Employed (ROCE)

ProQR Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ProQR Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ProQR Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ProQR Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ProQR Therapeutics stock

What is the ROCE (Return on Capital Employed) of ProQR Therapeutics this year?

The ROCE of ProQR Therapeutics is -0.77 undefined this year.

How has the ROCE (Return on Capital Employed) of ProQR Therapeutics developed compared to the previous year?

The ROCE of ProQR Therapeutics has increased by -22.1% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of ProQR Therapeutics?

A high Return on Capital Employed (ROCE) indicates that ProQR Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of ProQR Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that ProQR Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from ProQR Therapeutics impact the company?

An increase in the ROCE of ProQR Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of ProQR Therapeutics affect the company?

A decrease in ROCE of ProQR Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of ProQR Therapeutics?

Some factors that can affect ProQR Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of ProQR Therapeutics so important for investors?

The ROCE of ProQR Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can ProQR Therapeutics take to improve the ROCE?

To improve the ROCE, ProQR Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does ProQR Therapeutics pay?

Over the past 12 months, ProQR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProQR Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of ProQR Therapeutics?

The current dividend yield of ProQR Therapeutics is .

When does ProQR Therapeutics pay dividends?

ProQR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProQR Therapeutics?

ProQR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ProQR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProQR Therapeutics located?

ProQR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProQR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProQR Therapeutics from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did ProQR Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of ProQR Therapeutics in the year 2023?

In the year 2023, ProQR Therapeutics distributed 0 EUR as dividends.

In which currency does ProQR Therapeutics pay out the dividend?

The dividends of ProQR Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ProQR Therapeutics

Our stock analysis for ProQR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProQR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.